Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06451419
Other study ID # 5564
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 1, 2024
Est. completion date August 31, 2026

Study information

Verified date June 2024
Source Universidad Francisco de Vitoria
Contact Inés Muro, MD
Phone 915202416
Email ines.muro@salud.madrid.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to describe non motor symptoms in a prospective study of patients with Parkinson's disease associated to glucocerebrosidase (GBA-PD) mutations. The main questions it aims to answer are: - Do GBA-PD patients have a greater burden of non motor symptoms? - How do these non motor symptoms evolve during a prospective follow up of two years? - Are these non motor symptoms different from those that affect Parkinson's disease patients without glucocerebrosidase mutations (non GBA-PD), in prevalence, severity and type? - Do these non motor symptoms correlate with objective measures such as posturography or speed reaction tests? - Is there a test or combination of tests that can predict the appearance of early or severe non motor symptoms? For this reason researchers will compare the GBA-PD group of patients with a group of non mutated GBA Parkinson disease. Participants will undergo a neurological and neuropsychological evaluation with different tests in subsequent visits for a total of 2 years.


Description:

Parkinson's disease is the second most prevalent neurodegenerative disorder worldwide. Up to date, the main risk factor for its development is carrying an heterozygous mutation in glucocerebrosidase gene (GBA). GBA codifies for a GC-ase protein that takes part in lysosomal function. The homozygous mutation of this gene gives rise to Gaucher disease, which is a lysosomal disorder. This gene has also been associated with Lewy body dementia. The presence of an heterozygous mutation in GBA in Parkinson's disease can be found in up to 5-15% of the patients, depending on age and ethnicity. It has been described that those patients carrying the mutation can have an earlier debut of the disease. According to non motor symptoms, patients are prone to develop earlier and more severe motor symptoms. This has been studied specially in cognitive impairment but also dysautonomia, impulse control disorder and others. In relation to cognitive impairment these patients usually develop an earlier and more severe affection, reaching dementia states earlier in the disease. Some studies have described a worsening in cognitive function in GBA mutated patients after deep brain stimulation (DBS) to treat parkinsonian symptoms. This prevents patients from being candidates to therapies such as DBS. For this reason, the investigators consider it important to make a proper description of non motor symptoms in GBA mutated parkinsonian patients, since this finding can help to delineate the prognosis and choose individualized treatments, regarding the suggested differences with other Parkinson's disease patients. It is an observational prospective cohort study. Participants will be collected from a subgroup of patients that have agreed to undertake a genetic test including a panel of genes associated to Parkinson's disease. According to the results, patients will be subdivided in two groups according to their genetic status: - GBA heterozygous mutations - Absence of genetic mutations These patients will undergo neurologic evaluations, neuropsychological evaluations and self-administered evaluations. There will be no intervention. The pharmacologic and other type of treatment assessments will be conducted during their regular follow up with their neurologist. These visits will be repeated every 6 months for a total of 2 years. Total of 5 visits for each patient.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date August 31, 2026
Est. primary completion date June 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Aged over 18 years old. - Fulfill Parkinson's disease criteria of Movement Disorder Society 2015. - Parkinson's disease symptoms began before they were 70 and/or Parkinson's disease family history. - Underwent a genetic test of Parkinson's disease related genes. - Heterozygous mutation of glucocerebrosidase gene (only cases). - Absence of mutation in the Parkinson's disease genetic test (only controls). Exclusion Criteria: - Suspicion of atypical parkinsonism. - Personal history of other neurodegenerative disorders such as Alzheimer's disease. - Personal history of significant cerebrovascular damage, intracraneal lessions or important craneoencephalic trauma. - Deep brain stimulation treatment for Parkinson's disease. - Moderate or severe dementia that precludes from performing the tests.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Tests on non motor symptoms
Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.

Locations

Country Name City State
Spain Hospital Universitario La Princesa Madrid
Spain Universidad Francisco de Vitoria Pozuelo De Alarcón Madrid

Sponsors (2)

Lead Sponsor Collaborator
Juan Pablo Romero. MD, PhD Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Country where clinical trial is conducted

Spain, 

References & Publications (7)

Barkhuizen M, Anderson DG, Grobler AF. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies. Neurochem Int. 2016 Feb;93:6-25. doi: 10.1016/j.neuint.2015.12.004. Epub 2015 Dec 30. — View Citation

Brockmann K, Srulijes K, Pflederer S, Hauser AK, Schulte C, Maetzler W, Gasser T, Berg D. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov Disord. 2015 Mar;30(3):407-11. doi: 10.1002/ — View Citation

Leocadi M, Canu E, Donzuso G, Stojkovic T, Basaia S, Kresojevic N, Stankovic I, Sarasso E, Piramide N, Tomic A, Markovic V, Petrovic I, Stefanova E, Kostic VS, Filippi M, Agosta F. Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years — View Citation

Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium. Features of GBA-associated Parkinson's disease at presenta — View Citation

Ren J, Zhou G, Wang Y, Zhang R, Guo Z, Zhou H, Zheng H, Sun Y, Ma C, Lu M, Liu W. Association of GBA genotype with motor and cognitive decline in Chinese Parkinson's disease patients. Front Aging Neurosci. 2023 Feb 10;15:1091919. doi: 10.3389/fnagi.2023.1 — View Citation

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griff — View Citation

Swan M, Doan N, Ortega RA, Barrett M, Nichols W, Ozelius L, Soto-Valencia J, Boschung S, Deik A, Sarva H, Cabassa J, Johannes B, Raymond D, Marder K, Giladi N, Miravite J, Severt W, Sachdev R, Shanker V, Bressman S, Saunders-Pullman R. Neuropsychiatric ch — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in non motor symptoms scale from baseline to 2 years To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. 2 years
Primary Change in non motor symptoms scale from baseline to 6 months To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. 6 months
Primary Change in non motor symptoms scale from 6 months to 1 year To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. 6 months
Primary Change in non motor symptoms scale from 12 months to 18 months To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. 6 months
Primary Change in non motor symptoms scale from 18 months to 24 months To determine the non motor symptoms profile and its evolution through non motor symptoms scale in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 30 items with total scores from 0 to 360, higher scores meaning higher non motor symptoms burden. 6 months
Secondary Change in Montreal Cognitive Assessment scale from baseline to 2 years To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. 2 years
Secondary Change in Montreal Cognitive Assessment scale from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Montreal Cognitive Assessment scale from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Montreal Cognitive Assessment scale from12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Montreal Cognitive Assessment scale from18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Montreal Cognitive Assessment. Scores ranging from 0 to 30, with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Parkinson's disease cognitive rating scale from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. 2 years
Secondary Change in Parkinson's disease cognitive rating scale from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Parkinson's disease cognitive rating scale from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Parkinson's disease cognitive rating scale from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Parkinson's disease cognitive rating scale from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease cognitive rating scale, scores from 0 to 134 with lower scores meaning higher cognitive decline. 6 months
Secondary Change in Line Orientation Judgement scale from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. 2 years
Secondary Change in Line Orientation Judgement scale from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. 6 months
Secondary Change in Line Orientation Judgement scale from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. 6 months
Secondary Change in Line Orientation Judgement scale from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. 6 months
Secondary Change in Line Orientation Judgement scale from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Line Orientation Judgement, scores from 0 to 30 with lower punctuation meaning higher right hemisphere disfunction. 6 months
Secondary Change in Rey figure from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. 2 years
Secondary Change in Rey figure from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. 6 months
Secondary Change in Rey figure from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. 6 months
Secondary Change in Rey figure from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. 6 months
Secondary Change in Rey figure from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rey figure test, scoring from 0 to 72 points, meaning lower punctuations altered visuoperception and visual episodic memory. 6 months
Secondary Change in Weschler Memory test from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. 2 years
Secondary Change in Weschler Memory test from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. 6 months
Secondary Change in Weschler Memory test from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. 6 months
Secondary Change in Weschler Memory test from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. 6 months
Secondary Change in Weschler Memory test from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Weschler Memory test, scoring in relation to age with percentiles from 0 to 100, lower percentile meaning a greater memory disturbance. 6 months
Secondary Change in Stroop test from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. 2 years
Secondary Change in Stroop test from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. 6 months
Secondary Change in Stroop test from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. 6 months
Secondary Change in Stroop test from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. 6 months
Secondary Change in Stroop test from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Stroop test with T-scores from 0 to 100, higher scores reflecting better performance and less interference on reading ability. 6 months
Secondary Change in Trail Making Test A from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. 2 years
Secondary Change in Trail Making Test B from baseline to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. 2 years
Secondary Change in Trail Making Test A from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test B from baseline to 6 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test A from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test B from 6 months to 12 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test A from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test B from 12 months to 18 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test A from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test A, with scores ranging from 0 to 100 seconds, lower scores meaning better performance. 6 months
Secondary Change in Trail Making Test B from 18 months to 24 months To determine the cognitive profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Trail Making Test B, with scores ranging from 0 to 300 seconds, lower scores meaning better performance. 6 months
Secondary Change in Questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP-RS) from baseline to 2 years To determine impulse control disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using the Questionnaire for impulsive-compulsive disorders, scoring from 0 to 16 with lower scores meaning less impulsive-compulsive symptoms. 2 years
Secondary Change in Questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP-RS) from baseline to 6 months To determine impulse control disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using the Questionnaire for impulsive-compulsive disorders, scoring from 0 to 16 with lower scores meaning less impulsive-compulsive symptoms. 6 months
Secondary Change in Questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP-RS) from 6 months to 12 months To determine impulse control disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using the Questionnaire for impulsive-compulsive disorders, scoring from 0 to 16 with lower scores meaning less impulsive-compulsive symptoms. 6 months
Secondary Change in Questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP-RS) from 12 months to 18 months To determine impulse control disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using the Questionnaire for impulsive-compulsive disorders, scoring from 0 to 16 with lower scores meaning less impulsive-compulsive symptoms. 6 months
Secondary Change in Questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP-RS) from 18 months to 24 months To determine impulse control disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using the Questionnaire for impulsive-compulsive disorders, scoring from 0 to 16 with lower scores meaning less impulsive-compulsive symptoms. 6 months
Secondary Change in Neuropsychiatric inventory from baseline to 2 years To determine neuropsychiatric profile in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Neuropsychiatric inventory, scoring from 0 to 144 with higher scores meaning greater neuropsychiatric symptoms. 2 years
Secondary Change in Neuropsychiatric inventory from baseline to 6 months To determine neuropsychiatric profile in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Neuropsychiatric inventory, scoring from 0 to 144 with higher scores meaning greater neuropsychiatric symptoms. 6 months
Secondary Change in Neuropsychiatric inventory from 6 months to 12 months To determine neuropsychiatric profile in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Neuropsychiatric inventory, scoring from 0 to 144 with higher scores meaning greater neuropsychiatric symptoms. 6 months
Secondary Change in Neuropsychiatric inventory from 12 months to 18 months To determine neuropsychiatric profile in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Neuropsychiatric inventory, scoring from 0 to 144 with higher scores meaning greater neuropsychiatric symptoms. 6 months
Secondary Change in Neuropsychiatric inventory from 18 months to 24 months To determine neuropsychiatric profile in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Neuropsychiatric inventory, scoring from 0 to 144 with higher scores meaning greater neuropsychiatric symptoms. 6 months
Secondary Change in Apathy Evaluation Scale from baseline to 24 months To determine changes in apathy in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Apathy Evaluation Scale. The total score ranges from 18 to 72, with higher scores indicating more apathy. 2 years
Secondary Change in Apathy Evaluation Scale from baseline to 6 months To determine changes in apathy in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Apathy Evaluation Scale. The total score ranges from 18 to 72, with higher scores indicating more apathy. 6 months
Secondary Change in Apathy Evaluation Scale from 6 months to 12 months To determine changes in apathy in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Apathy Evaluation Scale. The total score ranges from 18 to 72, with higher scores indicating more apathy. 6 months
Secondary Change in Apathy Evaluation Scale from 12 months to 18 months To determine changes in apathy in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Apathy Evaluation Scale. The total score ranges from 18 to 72, with higher scores indicating more apathy. 6 months
Secondary Change in Apathy Evaluation Scale from 18 months to 24 months To determine changes in apathy in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Apathy Evaluation Scale. The total score ranges from 18 to 72, with higher scores indicating more apathy. 6 months
Secondary Change in Beck Depression Inventory from baseline to 24 months To determine changes in depression in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Beck Depression Inventory with scores from 0 to 63, with higher scores meaning more depressive symptoms. 2 years
Secondary Change in Beck Depression Inventory from baseline to 6 months To determine changes in depression in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Beck Depression Inventory with scores from 0 to 63, with higher scores meaning more depressive symptoms. 6 months
Secondary Change in Beck Depression Inventory from 6 months to 12 months To determine changes in depression in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Beck Depression Inventory with scores from 0 to 63, with higher scores meaning more depressive symptoms. 6 months
Secondary Change in Beck Depression Inventory from 12 months to 18 months To determine changes in depression in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Beck Depression Inventory with scores from 0 to 63, with higher scores meaning more depressive symptoms. 6 months
Secondary Change in Beck Depression Inventory from 18 months to 24 months To determine changes in depression in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Beck Depression Inventory with scores from 0 to 63, with higher scores meaning more depressive symptoms. 6 months
Secondary Change in Stai-trait Anxiety Inventory from baseline to 24 months To determine changes in anxiety in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using State-trait Anxiety Inventory, scoring from 20 to 80, with higher punctuations meaning higher anxiety symptoms. 2 years
Secondary Change in Stai-trait Anxiety Inventory from baseline to 6 months To determine changes in anxiety in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using State-trait Anxiety Inventory, scoring from 20 to 80, with higher punctuations meaning higher anxiety symptoms. 6 months
Secondary Change in Stai-trait Anxiety Inventory from 6 months to 12 months To determine changes in anxiety in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using State-trait Anxiety Inventory, scoring from 20 to 80, with higher punctuations meaning higher anxiety symptoms. 6 months
Secondary Change in Stai-trait Anxiety Inventory from 12 months to 18 months To determine changes in anxiety in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using State-trait Anxiety Inventory, scoring from 20 to 80, with higher punctuations meaning higher anxiety symptoms. 6 months
Secondary Change in Stai-trait Anxiety Inventory from 18 months to 24 months To determine changes in anxiety in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using State-trait Anxiety Inventory, scoring from 20 to 80, with higher punctuations meaning higher anxiety symptoms. 6 months
Secondary Change in Parkinson's disease sleep scale from baseline to 24 months To determine the sleep profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease sleep scale, with scores from 0 to 150, the highest meaning less sleep symptoms. 2 years
Secondary Change in Parkinson's disease sleep scale from baseline to 6 months To determine the sleep profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease sleep scale, with scores from 0 to 150, the highest meaning less sleep symptoms. 6 months
Secondary Change in Parkinson's disease sleep scale from 6 months to 12 months To determine the sleep profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease sleep scale, with scores from 0 to 150, the highest meaning less sleep symptoms. 6 months
Secondary Change in Parkinson's disease sleep scale from 12 months to 18 months To determine the sleep profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease sleep scale, with scores from 0 to 150, the highest meaning less sleep symptoms. 6 months
Secondary Change in Parkinson's disease sleep scale from 18 months to 24 months To determine the sleep profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Parkinson's disease sleep scale, with scores from 0 to 150, the highest meaning less sleep symptoms. 6 months
Secondary Change in Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire from baseline to 24 months To determine the presence and symptoms of Rapid Eye Movement Sleep Behaviour Disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rapid Eye Movement Sleep Screening Questionnaire, scoring from 0 to 13 with higher scores meaning more Rapid Eye Movement sleep problems. 2 years
Secondary Change in REM Sleep Behavior Disorder Screening Questionnaire from baseline to 6 months To determine the presence and symptoms of Rapid Eye Movement Sleep Behaviour Disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rapid Eye Movement Sleep Screening Questionnaire, scoring from 0 to 13 with higher scores meaning more Rapid Eye Movement sleep problems. 6 months
Secondary Change in REM Sleep Behavior Disorder Screening Questionnaire from to 6 months to 12 months To determine the presence and symptoms of Rapid Eye Movement Sleep Behaviour Disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rapid Eye Movement Sleep Screening Questionnaire, scoring from 0 to 13 with higher scores meaning more Rapid Eye Movement sleep problems. 6 months
Secondary Change in REM Sleep Behavior Disorder Screening Questionnaire from to 12 months to 18 months To determine the presence and symptoms of Rapid Eye Movement Sleep Behaviour Disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rapid Eye Movement Sleep Screening Questionnaire, scoring from 0 to 13 with higher scores meaning more Rapid Eye Movement sleep problems. 6 months
Secondary Change in REM Sleep Behavior Disorder Screening Questionnaire from to 18 months to 24 months To determine the presence and symptoms of Rapid Eye Movement Sleep Behaviour Disorder in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Rapid Eye Movement Sleep Screening Questionnaire, scoring from 0 to 13 with higher scores meaning more Rapid Eye Movement sleep problems. 6 months
Secondary Change in Epworth Sleepiness Scale from baseline to 24 months To determine the presence and severity of somnolence in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Epworth Sleepiness Scale, scoring from 0 to 24, with higher scores meaning higher sleeppiness. 2 years
Secondary Change in Epworth Sleepiness Scale from baseline to 6 months To determine the presence and severity of somnolence in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Epworth Sleepiness Scale, scoring from 0 to 24, with higher scores meaning higher sleeppiness. 6 months
Secondary Change in Epworth Sleepiness Scale from 6 months to 12 months To determine the presence and severity of somnolence in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Epworth Sleepiness Scale, scoring from 0 to 24, with higher scores meaning higher sleeppiness. 6 months
Secondary Change in Epworth Sleepiness Scale from 12 months to 18 months To determine the presence and severity of somnolence in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Epworth Sleepiness Scale, scoring from 0 to 24, with higher scores meaning higher sleeppiness. 6 months
Secondary Change in Epworth Sleepiness Scale from 18 months to 24 months To determine the presence and severity of somnolence in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Epworth Sleepiness Scale, scoring from 0 to 24, with higher scores meaning higher sleeppiness. 6 months
Secondary Change in Restless Legs Syndrome Rating Scale from baseline to 24 months To determine the presence and severity of restless leg syndrome in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Restless Legs Syndrome Rating Scale, scoring from 0 to 40 with higher scores meaning greater restless legs syndrome symptoms. 2 years
Secondary Change in Restless Legs Syndrome Rating Scale from baseline to 6 months To determine the presence and severity of restless leg syndrome in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Restless Legs Syndrome Rating Scale, scoring from 0 to 40 with higher scores meaning greater restless legs syndrome symptoms. 6 months
Secondary Change in Restless Legs Syndrome Rating Scale from 6 months to 12 months To determine the presence and severity of restless leg syndrome in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Restless Legs Syndrome Rating Scale, scoring from 0 to 40 with higher scores meaning greater restless legs syndrome symptoms. 6 months
Secondary Change in Restless Legs Syndrome Rating Scale from 12 months to 18 months To determine the presence and severity of restless leg syndrome in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Restless Legs Syndrome Rating Scale, scoring from 0 to 40 with higher scores meaning greater restless legs syndrome symptoms. 6 months
Secondary Change in Restless Legs Syndrome Rating Scale from 18 months to 24 months To determine the presence and severity of restless leg syndrome in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Restless Legs Syndrome Rating Scale, scoring from 0 to 40 with higher scores meaning greater restless legs syndrome symptoms. 6 months
Secondary Change in Berg balance scale from baseline to 24 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Berg Balance scale with ranges from 0 to 56. The lower score, the more at risk you of losing balance. 2 years
Secondary Change in Berg balance scale from baseline to 6 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Berg Balance scale with ranges from 0 to 56. The lower score, the more at risk you of losing balance. 6 months
Secondary Change in Berg balance scale from 6 months to 12 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Berg Balance scale with ranges from 0 to 56. The lower score, the more at risk you of losing balance. 6 months
Secondary Change in Berg balance scale from 12 months to 18 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Berg Balance scale with ranges from 0 to 56. The lower score, the more at risk you of losing balance. 6 months
Secondary Change in Berg balance scale from 18 months to 24 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using Berg Balance scale with ranges from 0 to 56. The lower score, the more at risk you of losing balance. 6 months
Secondary Change in limits of stability from baseline to 24 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using % of performance regarding normalized limits of stability for reference sample, with values between 0-100% 2 years
Secondary Change in limits of stability from baseline to 6 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using % of performance regarding normalized limits of stability for reference sample, with values between 0-100% 6 months
Secondary Change in limits of stability from 6 months to 12 months TTo determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using % of performance regarding normalized limits of stability for reference sample, with values between 0-100% 6 months
Secondary Change in limits of stability from 12 months to 18 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using % of performance regarding normalized limits of stability for reference sample, with values between 0-100% 6 months
Secondary Change in limits of stability from 18 months to 24 months To determine changes in balance in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using % of performance regarding normalized limits of stability for reference sample, with values between 0-100% 6 months
Secondary Change in speed reaction test from baseline to 24 months To determine changes in speed reaction in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using speed reaction tests measuring the time until response in seconds, with scores from 0 with no maximum value. 2 years
Secondary Change in speed reaction test from baseline to 6 months TTo determine changes in speed reaction in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using speed reaction tests measuring the time until response in seconds, with scores from 0 with no maximum value. 6 months
Secondary Change in speed reaction test from 6 months to 12 months To determine changes in speed reaction in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using speed reaction tests measuring the time until response in seconds, with scores from 0 with no maximum value. 6 months
Secondary Change in speed reaction test from 12 months to 18 months To determine changes in speed reaction in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using speed reaction tests measuring the time until response in seconds, with scores from 0 with no maximum value. 6 months
Secondary Change in speed reaction test from 18 months to 24 months To determine changes in speed reaction in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations, by using speed reaction tests measuring the time until response in seconds, with scores from 0 with no maximum value. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II scale from baseline to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II, scoring from 0 to 52, higher scores meaning a greater Parkinson's symptoms burden. 2 years
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II from baseline to 6 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II, scoring from 0 to 52, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II from 6 months to 12 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II, scoring from 0 to 52, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II from 12 months to 18 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II, scoring from 0 to 52, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II from 18 months to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part II, scoring from 0 to 52, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III scale from baseline to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III, scoring from 0 to 132, higher scores meaning a greater Parkinson's symptoms burden. 2 years
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III scale from baseline to 6 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III, scoring from 0 to 132, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III scale from 6 months to 12 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III, scoring from 0 to 132, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III scale from 12 months to 18 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III, scoring from 0 to 132, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III scale from 18 months to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part III, scoring from 0 to 132, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV scale from baseline to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV, scoring from 0 to 24, higher scores meaning a greater Parkinson's symptoms burden. 2 years
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV scale from baseline to 6 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV, scoring from 0 to 24, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV scale from 6 months to 12 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV, scoring from 0 to 24, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale pary IV scale from 12 months to 18 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV, scoring from 0 to 24, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV scale from 18 months to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Movement Disorder's Society- Unified Parkinson's Disease Rating Scale part IV, scoring from 0 to 24, higher scores meaning a greater Parkinson's symptoms burden. 6 months
Secondary Change in Hoehn and Yahr scale from baseline to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Hoehn and Yahr scale, scores from 1-5, with lower scores meaning a lower motor symptom burden. 2 years
Secondary Change in Hoehn and Yahr scale from baseline to 6 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Hoehn and Yahr scale, scores from 1-5, with lower scores meaning a lower motor symptom burden. 6 months
Secondary Change in Hoehn and Yahr scale from 6 months to 12 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Hoehn and Yahr scale, scores from 1-5, with lower scores meaning a lower motor symptom burden. 6 months
Secondary Change in Hoehn and Yahr scale from 12 months to 18 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Hoehn and Yahr scale, scores from 1-5, with lower scores meaning a lower motor symptom burden. 6 months
Secondary Change in Hoehn and Yahr scale from 18 months to 24 months To determine the motor profile of glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Hoehn and Yahr scale, scores from 1-5, with lower scores meaning a lower motor symptom burden. 6 months
Secondary Change in Parkinson's disease Questionnaire-39 from baseline to 24 months To determine the repercusion of Parkinson's disease in daily activies in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Parkinson's disease Questionnaire-39, scores from 0 to 100 with higher scores meaning greater repercussion in daily activities. 2 years
Secondary Change in Parkinson's disease Questionnaire-39 from baseline to 6 months To determine the repercusion of Parkinson's disease in daily activies in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Parkinson's disease Questionnaire-39, scores from 0 to 100 with higher scores meaning greater repercussion in daily activities. 6 months
Secondary Change in Parkinson's disease Questionnaire-39 from 6 months to 12 months To determine the repercusion of Parkinson's disease in daily activies in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Parkinson's disease Questionnaire-39, scores from 0 to 100 with higher scores meaning greater repercussion in daily activities. 6 months
Secondary Change in Parkinson's disease Questionnaire-39 from 12 months to 18 months To determine the repercusion of Parkinson's disease in daily activies in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Parkinson's disease Questionnaire-39, scores from 0 to 100 with higher scores meaning greater repercussion in daily activities. 6 months
Secondary Change in Parkinson's disease Questionnaire-39 from 18 months to 24 months To determine the repercusion of Parkinson's disease in daily activies in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations by using Parkinson's disease Questionnaire-39, scores from 0 to 100 with higher scores meaning greater repercussion in daily activities. 6 months
Secondary Change in number of Parkinson's disease treatments from baseline to 24 months To determine the changes in number of Parkinsons disease drugs during the course of the disease in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 2 years
Secondary Change in number of Parkinson's disease treatments from baseline to 6 months To determine the changes in number of Parkinsons disease drugs during the course of the disease in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 6 months
Secondary Change in number of Parkinson's disease treatments from 6 months to 12 months To determine the changes in number of Parkinsons disease drugs during the course of the disease in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 6 months
Secondary Change in number of Parkinson's disease treatments from 12 to 18 months To determine the changes in number of Parkinsons disease drugs during the course of the disease in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 6 months
Secondary Change in number of Parkinson's disease treatments from 18 to 24 months To determine the changes in number of Parkinsons disease drugs during the course of the disease in glucocerebrosidase mutated Parkinson's disease in comparison with those without mutations. 6 months
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A